Sowell Financial Services’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$200K Buy
+884
New +$157K 0.01% 1085
2021
Q2
Sell
-4,045
Closed -$1.36M 968
2021
Q1
$1.36M Buy
4,045
+57
+1% +$15.8K 0.05% 329
2020
Q4
$996K Sell
3,988
-291
-7% -$69.3K 0.04% 331
2020
Q3
$969K Sell
4,279
-544
-11% -$113K 0.05% 302
2020
Q2
$841K Sell
4,823
-320
-6% -$51.1K 0.05% 318
2020
Q1
$649K Buy
5,143
+3,136
+156% +$470K 0.05% 329
2019
Q4
$307K Buy
2,007
+396
+25% +$54.8K 0.02% 591
2019
Q3
$213K Buy
+1,611
New +$216K 0.02% 623
2019
Q1
$208K Buy
+1,434
New +$188K 0.02% 512

Other funds holding CRL

Sowell Financial Services's CRL Position: Q2 2026 in Review

Sowell Financial Services opened a new position in Charles River Laboratories (CRL) in Q2 2026: 884 shares worth $200K. The stake represents 0.01% of the portfolio and ranks #1085 among its holdings. This is a return to the name: Sowell Financial Services previously reported a position in CRL as recently as Q1 2021.

Sowell Financial Services first reported a position in CRL in Q1 2019 and has held it in 9 quarters since. The position peaked at $1.36M in Q1 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Sowell Financial Services held 884 shares of Charles River Laboratories worth $200K as of Q2 2026.
  • Charles River Laboratories was a new Sowell Financial Services position in Q2 2026.
  • Charles River Laboratories made up 0.01% of Sowell Financial Services's portfolio in Q2 2026, its #1085 holding.
  • Sowell Financial Services first reported a position in Charles River Laboratories in Q1 2019 and has held it in 9 quarters since.
  • Sowell Financial Services's Charles River Laboratories position peaked at $1.36M in Q1 2021.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Sowell Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.